Business
NKGen Biotech, Inc. to Transition from the Nasdaq Global Market to OTC Markets; Reverse Stock Split will not be Implemented
Trading commencing on the OTC Markets on March 5, 2025.Trading expected to continue under ticker symbol “NKGN” for common stock and “NKGNW” for warrants.NKGen Biotech, Inc. (“NKGen” or the “Company”) has regained compliance on its public reporting obligations with the filing of its most recent quarterly report on Form 10-Q on March 4, 2025; and intends to continue complying with all Securities and Exchange (“SEC”) reporting requirements.The Company has cancelled its previously announced 1-for-6
About this update from Nkgen Biotech Inc.
[{"type":"image","alt":"NKGen Biotech","displaySize":"","headline":null,"caption":"NKGen Biotech","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":88,"url":"https://media.zenfs.com/en/globenewswire.com/c1eac0af691f2ebb591766c4753f5c1d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/VkzwCPMCginQ0oB0dyjMLA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c1eac0af691f2ebb591766c4753f5c1d","width":300,"height":88}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Trading commencing on the OTC Markets on March 5, 2025.","length":55,"tagName":"p"}]},{"val":[{"type":"text","content":"Trading expected to continue under ticker symbol “NKGN” for common stock and “NKGNW” for warrants.","length":98,"tagName":"p"}]},{"val":[{"type":"text","content":"NKGen Biotech, Inc. (“NKGen” or the “Company”) has regained compliance on its public reporting obligations with the filing of its most recent quarterly report on Form 10-Q on March 4, 2025; and intends to continue complying with all Securities and Exchange (“SEC”) reporting requirements.","length":288,"tagName":"p"}]},{"val":[{"type":"text","content":"The Company has cancelled its previously announced 1-for-6 reverse stock split. ","length":79,"tagName":"p"}]},{"val":[{"type":"text","content":"Enrollment in randomized Phase 2a Alzheimer’s trial is expected to be completed by the end of Q2 with an initial readout planned for later in 2025.","length":147,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":667,"olType":false},{"type":"text","content":"SANTA ANA, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that on March 3, 2025 it received notice that the Nasdaq Hearings Panel determined to delist the Company’s common stock from the Nasdaq Global Market after the close of trading on March 4, 2025, solely due to the Company’s continued failure to comply with Rule 5450(b)(2)(A) of Nasdaq’s Listing Requirements, related to the market value of its common stock. After delisting from Nasdaq, the Company expects that the common stock will be traded on a market operated by the OTC Markets Group, Inc....